Editas Medicine announced on November 10, 2025 that it reported third‑quarter 2025 earnings, providing a snapshot of its financial position and outlining progress on its in‑vivo gene‑editing program.
The company highlighted that cash, cash equivalents, and marketable securities stood at $165.6 million as of September 30, 2025, down from $269.9 million at the end of 2024, but it expects the current cash to fund operations into the third quarter of 2027, extending its runway for pipeline development.
Editas also presented preclinical data at the American Heart Association and European Society of Gene & Cell Therapy meetings, showing that its lead candidate EDIT‑401 achieved over 90 % LDL‑C reduction in non‑human primates. The company remains on track to file an investigational new drug application by mid‑2026 and to obtain initial human proof‑of‑concept data by year‑end 2026.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.